President Trump’s decision to name Kyle Diamantas acting FDA commissioner immediately after Marty Makary’s May 2026 departure has positioned the deputy for food as the clear frontrunner in the nomination market. Administration officials are now accelerating the search for a permanent successor, with plans to recommend a candidate to the president by early June to stabilize agency leadership ahead of midterm pressures. This rapid timeline and Diamantas’s current role, backed by direct presidential endorsement, explain the 53% trader consensus favoring his formal announcement. Delays in finalizing a Senate-confirmable pick keep the “no announcement by December 31” outcome at 14%, while lower probabilities for prior figures like Stephen Hahn and Brett Giroir reflect their limited recent involvement in the selection process.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoKyle Diamantas 58%
No announcement by December 31 7.0%
Stephen Hahn 7%
Brett Giroir 3.5%
NUEVO
NUEVO
31 dic 2026
Kyle Diamantas
58%
Stephen Hahn
7%
Brett Giroir
3%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
7%
Kyle Diamantas 58%
No announcement by December 31 7.0%
Stephen Hahn 7%
Brett Giroir 3.5%
NUEVO
NUEVO
31 dic 2026
Kyle Diamantas
$1,515 Vol.
58%
Stephen Hahn
$975 Vol.
7%
Brett Giroir
$1,510 Vol.
3%
Grace Graham
$1,842 Vol.
3%
Sara Brenner
$848 Vol.
3%
No announcement by December 31
$533 Vol.
7%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s decision to name Kyle Diamantas acting FDA commissioner immediately after Marty Makary’s May 2026 departure has positioned the deputy for food as the clear frontrunner in the nomination market. Administration officials are now accelerating the search for a permanent successor, with plans to recommend a candidate to the president by early June to stabilize agency leadership ahead of midterm pressures. This rapid timeline and Diamantas’s current role, backed by direct presidential endorsement, explain the 53% trader consensus favoring his formal announcement. Delays in finalizing a Senate-confirmable pick keep the “no announcement by December 31” outcome at 14%, while lower probabilities for prior figures like Stephen Hahn and Brett Giroir reflect their limited recent involvement in the selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Mercado abierto: May 12, 2026, 7:59 PM ET
Volumen
$7,223Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s decision to name Kyle Diamantas acting FDA commissioner immediately after Marty Makary’s May 2026 departure has positioned the deputy for food as the clear frontrunner in the nomination market. Administration officials are now accelerating the search for a permanent successor, with plans to recommend a candidate to the president by early June to stabilize agency leadership ahead of midterm pressures. This rapid timeline and Diamantas’s current role, backed by direct presidential endorsement, explain the 53% trader consensus favoring his formal announcement. Delays in finalizing a Senate-confirmable pick keep the “no announcement by December 31” outcome at 14%, while lower probabilities for prior figures like Stephen Hahn and Brett Giroir reflect their limited recent involvement in the selection process.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$7,223Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s decision to name Kyle Diamantas acting FDA commissioner immediately after Marty Makary’s May 2026 departure has positioned the deputy for food as the clear frontrunner in the nomination market. Administration officials are now accelerating the search for a permanent successor, with plans to recommend a candidate to the president by early June to stabilize agency leadership ahead of midterm pressures. This rapid timeline and Diamantas’s current role, backed by direct presidential endorsement, explain the 53% trader consensus favoring his formal announcement. Delays in finalizing a Senate-confirmable pick keep the “no announcement by December 31” outcome at 14%, while lower probabilities for prior figures like Stephen Hahn and Brett Giroir reflect their limited recent involvement in the selection process.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes